PE-22-28: what the research shows
- By Reed Calder
- Last reviewed Nov 13, 2026
- 31 studies and official documents checked
In short
PE-22-28 (also called mini-spadin) is a lab-made peptide of seven amino acids, cut down from spadin, a peptide made from the sortilin protein. It is sold online as a fast-acting mood and “neurogenesis” peptide. In cells it blocks a potassium channel called TREK-1 far more strongly than spadin does. In male mice, one lab found it shortened immobility in a forced-swim test and raised new brain cells after four days. We found four papers on PE-22-28 itself, all from one research group in France, and none in people. The “23 hours” figure belongs to modified versions at higher doses, the “faster than antidepressants” comparison wasn’t run in the paper, and in a stroke study its channel recordings showed low concentrations raising TREK-1 activity instead of blocking it, while a ten-times-higher early dose was followed by more deaths. It isn’t FDA-approved, and no registered trial lists it.
EvidenceCellAnimalHumanfour papers, one group; none in people
You’ll often read that PE-22-28 is a piece of galanin or the same as tirzepatide, builds new brain cells faster than antidepressants, lasts 23 hours, helps muscle and stroke recovery and comes as a nasal spray. This page covers what it is, what each study tested, what the 23-hour and four-day numbers really are, and where it stands legally.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| PE-22-28, PE 22-28 | The code name: the seven amino acids at positions 22 to 28 of a peptide called PE (Djillani et al., 2017) | No study found |
| Mini-spadin | The developers’ other name for the same sequence (Mazella et al., 2018). The stroke and pancreas papers use it and name PE-22-28 in the text, but give too little chemical detail for us to confirm the exact material (Pietri et al., 2019; Daziano et al., 2021) | No study found |
| Spadin | The longer parent, 17 amino acids, made from the sortilin protein (Mazella et al., 2010) | No study found |
| G/A-PE 22-28 and biotinylated G/A-PE 22-28 | Modified versions. The “23 hours” and 21-hour figures belong to these (Djillani et al., 2017) | No study found |
| PE, the sortilin propeptide | The body’s own peptide that spadin comes from; blood levels have been measured in people (Devader et al., 2017; Roulot et al., 2018; Mazella et al., 2025) | Measured, not given |
| Galanin, tirzepatide | Different peptides that some pages confuse with PE-22-28; it is neither | Not this page |
| Vials, sprays and other products sold online | Forms sold under the PE-22-28 name | No study of these products found |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. A seller catalog lists a different CAS number, 1234388-01-0, for the same formula.
| Form | CAS number | Registry record |
|---|---|---|
| PE-22-28 (mini-spadin) | 1801959-12-5 | PubChem |
What PE-22-28 is
PE-22-28 is seven amino acids: glycine, valine, serine, tryptophan, glycine, leucine and arginine. It weighs about 774 daltons (PubChem). The body makes a protein called sortilin and cuts a propeptide from it. In 2010 a French lab reported that a 17-amino-acid piece of it, spadin, blocks a nerve-cell potassium channel called TREK-1 and acts like an antidepressant in mice (Mazella et al., 2010).
Spadin faded within hours in mice, so the same lab designed PE-22-28 from the pieces spadin breaks into in blood (Djillani et al., 2017). TREK-1 is open when a nerve cell is at rest. Mice with the gene deleted resisted depression in five behavior tests (Heurteaux et al., 2006), which is why blockers were tried.
Nothing in that chain has been tested in people.
What has been studied
In people: none
- No study of PE-22-28 or spadin given to a person. We searched PubMed and ClinicalTrials.gov (ClinicalTrials.gov search).
- The body’s own propeptide has been measured, in three small observational groups. In 37 people with depression and 49 healthy volunteers, blood levels were lower in depression (18.9 against 23.7 nanomolar, p = 0.035) and rose a little after 12 weeks of antidepressants (to 21.0, p = 0.047); the rise didn’t track the change in symptom scores (r = 0.18, p = 0.27) (Devader et al., 2017). In 45 people with treatment-resistant depression, levels didn’t differ from healthy volunteers and rose about a month after electroconvulsive therapy in those who responded, and not in those who didn’t (Roulot et al., 2018). In 204 stroke patients, levels were lower in those with depression at each of four visits (13.0 against 15.6 nanomolar at six months, 11.8 against 14.5 at five years) and were linked with depression scores but not anxiety scores; follow-up shrank from 157 people at six months to 56 at five years (Mazella et al., 2025). The blood test in the 2017 depression study didn’t detect PE-22-28 itself. These measure a natural peptide, not PE-22-28.
In mice and rats
- Despair tests, 2017. In male mice, one injection of 3.0 to 4.0 micrograms per kilogram cut immobility in a forced-swim test to 91.8 seconds against 161.7 on saline (10 mice per group). It also worked by mouth at 1 milligram per kilogram; the figure legend gives a different injected amount than the text (100 against 3.0 micrograms per kilogram). Four days of treatment shortened escape latency in a learned-helplessness test and the time to eat in a novelty-suppressed-feeding test (Djillani et al., 2017).
- A second forced-swim result, 2017. A blood-marker paper from the same group also tested PE-22-28 in mice: injected into a vein, it cut immobility in a forced-swim test against saline (p < 0.0001; 10 to 12 mice per group) (Devader et al., 2017).
- New brain cells, 2017. After four days at 3.0 to 4.0 micrograms per kilogram, mice had 1,736 new cells in the hippocampus against 899 on saline (5 per group). The paper cites “3 to 4 weeks” for conventional antidepressants from earlier work; it didn’t test one alongside (Djillani et al., 2017).
- How long, 2017. Two modified versions, at 32 and 40 micrograms per kilogram, kept working for about 21 and 23 hours (the Results and figure give them in that order, the Discussion the reverse), against about 6 hours for spadin at 100 (Djillani et al., 2017). These are half-effect times on a behavior test, not blood half-lives, and they are not for plain PE-22-28.
- Stroke, 2019. Mice with a blocked brain artery got mini-spadin at a very low dose early (0.03 micrograms per kilogram), then a dose 100 times higher for mood. Channel recordings showed low concentrations raised TREK-1 activity and higher ones blocked it. Treated mice lost less weight, lost less of a dopamine-neuron marker in the substantia nigra, did better on some movement and memory tests and showed less later low-mood behavior. Time in the target area of the memory test didn’t differ (p = 0.187), and swimming speed and distance didn’t either. In a separate survival group, a ten-times-higher early dose (0.3 micrograms per kilogram) was followed by more deaths: 4 of 19 mice were alive at day 70, against 15 of 26 on saline and 15 of 20 on the low dose. The text says every mouse alive at day 4 survived to ten weeks, and the table shows deaths after day 4. The authors disclose being inventors on a patent application for propeptide pieces for depression (Pietri et al., 2019).
- The parent, spadin, outside the lab, 2018. Rats with stress-induced depressive behavior improved at least a week earlier on spadin or a different TREK-1 blocker than on fluoxetine. That test used spadin, not PE-22-28 (Qi et al., 2018).
- Spadin, mixed results from other labs, 2016 to 2021. In rats, spadin given into the spinal canal caused pain from touch in healthy animals, and spadin before a formalin injection increased flinching and later pain sensitivity (García et al., 2021; García et al., 2021). In mice, spadin removed the pain relief of a TREK-1 activator (Busserolles et al., 2020). Mice given spadin were more likely to get decompression sickness in a dive test (Vallée et al., 2016), and in rats with a brain injury spadin reduced the protection from a decompression surgery (Chen et al., 2021). These tests used spadin, not PE-22-28.
EvidenceCellAnimalHumanmale mice in the 2017 and 2019 studies; rats only for spadin
In dishes
- Strength, 2017. On human TREK-1 in kidney-derived cells, PE-22-28 blocked the channel with an IC50 of 0.12 nanomolar in the abstract and 0.1 in the Results, against 40 to 60 nanomolar for spadin. It left the heart-rhythm channel hERG alone at 10 micromolar (Djillani et al., 2017). Other labs tested spadin: in frog-egg cells it didn’t block basal TREK-1 current and only blocked the part activated by arachidonic acid (Ma et al., 2020), while in cells carrying human TREK-1, 1 micromolar reduced current (Gil et al., 2012).
- Synapses, 2017. In cultured mouse cortical neurons at 0.1 micromolar, a synapse marker (PSD-95) about doubled by 36 hours (Djillani et al., 2017).
- Pancreas cells, 2016 and 2021. In a rat insulin-making cell line, mini-spadin partly protected the cells from an inflammation signal and increased a marker of cell multiplication, which spadin did not (Daziano et al., 2021); the paper’s text and figures differ on some numbers and one drug concentration. Spadin raised glucose-driven insulin release in cells and mice (Hivelin et al., 2016).
- Fat cells, 2017 and 2025. Spadin had no effect on glucose uptake in a mouse fat-cell line (Hivelin et al., 2017). Blocking TREK-1 with spadin increased fat-cell development and fat build-up in cultured cells, and mice without TREK-1 gained more fat on a high-fat diet (Kim et al., 2025).
EvidenceCellAnimalHuman
All four papers on PE-22-28 itself come from the same research group near Nice (Heurteaux, Mazella and Borsotto among the authors) (Devader et al., 2017; Djillani et al., 2017; Pietri et al., 2019; Daziano et al., 2021). Tests from other labs used spadin, and several found it raised pain sensitivity or reduced protection.
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| It treats depression | Untested | In male mice it cut immobility in forced-swim and other despair tests (Djillani et al., 2017; Devader et al., 2017). We found no study in a person. These tests screen for antidepressant-like activity in rodents; they don’t show a person would feel better |
| It builds new brain cells in four days, faster than antidepressants | Mixed | Mice had 1,736 new hippocampal cells after four days against 899 on saline (Djillani et al., 2017). That paper didn’t test an antidepressant alongside. The one head-to-head with fluoxetine used spadin in rats (Qi et al., 2018) |
| It lasts 23 hours | Mixed | The 21 and 23 hours are half-effect times on a behavior test for two modified versions at 32 and 40 micrograms per kilogram, against about 6 hours for spadin at 100 (Djillani et al., 2017). The paper lists the two in opposite orders in its Results and Discussion, and reports an improved duration for plain PE-22-28 without giving that figure |
| It is hundreds of times more potent than spadin | Mixed | On human TREK-1 in cultured cells, IC50 was 0.12 nanomolar in the abstract and 0.1 in the Results, against 40 to 60 for spadin, so several hundred times (Djillani et al., 2017). The paper’s abstract and Results give different values for the same peptide. One cell line, one lab; potency in a dish isn’t effect in a person |
| It blocks the TREK-1 channel | Mixed | It did in cells (Djillani et al., 2017). In the stroke study’s channel recordings, low concentrations raised TREK-1 activity and higher ones blocked it (Pietri et al., 2019). For spadin, a 2020 frog-egg-cell study found no block of basal current, only of the part activated by arachidonic acid (Ma et al., 2020) |
| It protects the brain after a stroke | Mixed | In mice with a blocked artery, a low early dose of mini-spadin improved some movement, memory and later low-mood measures, but a ten-times-higher early dose was followed by more deaths (4 of 19 alive at day 70, against 15 of 26 on saline) and the memory-test target-area result didn’t differ (Pietri et al., 2019). One study, one group, no people |
| It improves muscle function or helps neurodegenerative disease | Untested | We found no study of PE-22-28 in muscle or in any neurodegenerative disease |
| It has fewer side effects than antidepressants | Untested | We found no safety study of PE-22-28 in any animal. It left a heart-rhythm channel alone in cells (Djillani et al., 2017), and spadin didn’t change infarct size, seizures or heart currents in mice (Moha Ou Maati et al., 2012). Mice without TREK-1 show both harm and benefit depending on the organ and injury (Fang et al., 2019; Zheng et al., 2022; Kamatham et al., 2019). Other labs found spadin raised pain sensitivity in rats and was linked to more decompression sickness in mice (García et al., 2021; Vallée et al., 2016), and the stroke study’s higher early dose was followed by more deaths (Pietri et al., 2019) |
| It is a piece of galanin | Contradicted | No. The 2017 paper designed it from the pieces spadin breaks into in blood, and galanin isn’t the source (Djillani et al., 2017) |
| PE-22-28 is tirzepatide | Contradicted | No. Tirzepatide is a much larger drug acting on GLP-1 and GIP receptors (see the tirzepatide page); PE-22-28 is seven amino acids that act on a potassium channel (Djillani et al., 2017) |
| It works as a nasal spray | Untested | The mice were injected or given it by mouth (Djillani et al., 2017). We found no study of a nasal route |
| It helps blood sugar or weight loss | Untested | Mini-spadin protected pancreas cells in dishes (Daziano et al., 2021), and spadin raised glucose-driven insulin in mice (Hivelin et al., 2016). In fat cells, spadin increased fat build-up (Kim et al., 2025) and had no effect on glucose uptake in another study (Hivelin et al., 2017). We found no study of PE-22-28 on blood sugar or weight in an animal or person |
| It works better stacked with Semax or Selank | Untested | No study tested it with either peptide |
| The microgram doses online come from research | Untested | The only doses we found are per kilogram of a mouse (Djillani et al., 2017; Pietri et al., 2019). Nobody has measured a dose in a person |
| It is FDA-approved | Contradicted | No. The FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA), and its safety-risk page doesn’t name it (FDA, 2026) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
PE-22-28 and spadin
| Spadin | PE-22-28 | G/A-PE 22-28 (modified) | |
|---|---|---|---|
| Amino acids | 17 | 7 | 7, with a changed end |
| Strength on human TREK-1 in cells | IC50 40 to 60 nM | IC50 0.1 to 0.12 nM (abstract against Results) | IC50 about 0.1 to 0.12 nM |
| How long the effect lasted in mice | About 6 hours at 100 micrograms per kilogram | Reported as improved; no separate figure found | About 21 hours at 32 micrograms per kilogram (the Discussion says 23) |
| Given to people | No study found | No study found | No study found |
A result for spadin isn’t a result for PE-22-28, and a result for a modified version isn’t either. The four papers on PE-22-28 itself are listed above. For other brain peptides, see the brain and sleep page.
What the studies used
| Study | What was tested | Amount reported |
|---|---|---|
| Djillani et al., 2017 | Male mice, forced swim | One injection of 3.0 to 4.0 micrograms per kilogram, or 1 milligram per kilogram by mouth (the figure legend gives 100 micrograms per kilogram for the injected route) |
| Devader et al., 2017 | Male mice, forced swim, injected into a vein | Not reported in the text we read |
| Djillani et al., 2017 | Male mice, four-day tests | 3.0 to 4.0 micrograms per kilogram a day for 4 days |
| Djillani et al., 2017 | Duration, modified versions | 32 and 40 micrograms per kilogram, against 100 for spadin |
| Pietri et al., 2019 | Stroke mice, mini-spadin | 0.03 micrograms per kilogram once a day for 7 days after the stroke, then 3 micrograms per kilogram four days a week; a survival group got 0.3 micrograms per kilogram early |
| Djillani et al., 2017 | Cells | 0.12 nanomolar blocked TREK-1; 0.1 micromolar on neurons; hERG tested at 10 micromolar |
A dose per kilogram of a mouse doesn’t convert into a dose for a person, and no study did that conversion. We found no blood-level, brain-level or dose-finding study in any animal or person. These are amounts from studies, not advice for anyone to use.
Side effects and safety
- In people. No study, so no reported side effects.
- PE-22-28 itself. We found no toxicology or safety study in any animal. In cells it left the hERG heart-rhythm channel alone at 10 micromolar (Djillani et al., 2017). The stroke study’s higher early dose was followed by more deaths (Pietri et al., 2019); that wasn’t designed as a safety test.
- The parent peptide. In one early mouse screen, spadin didn’t change pain, seizure threshold, infarct size, blood sugar or heart currents (Moha Ou Maati et al., 2012). Later work found spadin raised pain sensitivity in rats, removed a TREK-1 activator’s pain relief in mice and was linked to more decompression sickness (García et al., 2021; García et al., 2021; Busserolles et al., 2020; Vallée et al., 2016). That is spadin, not PE-22-28.
- The target. Mice without TREK-1 had worse blood-brain-barrier damage after a brain bleed and larger heart infarcts with a longer QT interval, but smaller strokes and less barrier breakdown after a blocked brain artery (Fang et al., 2019; Kamatham et al., 2019; Zheng et al., 2022). Deleting a gene isn’t the same as a drug, but it shows the channel does different jobs in different tissues.
- What is in the bottle. We found no independent analysis of PE-22-28 vials or sprays sold online.
- Not studied. Pregnancy, children, long-term use, mixing with antidepressants, nasal use, and any use in people.
Side effects people report from online products aren’t covered here; they come from users, not studies.
Legal and approval status
- Not an approved drug. The FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA), and its page of bulk substances that may present significant safety risks doesn’t name it (FDA, 2026).
- No registered trial. ClinicalTrials.gov lists no study of PE-22-28, spadin or mini-spadin (ClinicalTrials.gov search).
- Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
- Sport. The World Anti-Doping Agency’s 2026 list doesn’t name it, but its S0 class prohibits any substance with no government approval for human therapeutic use (WADA, 2026).
- “Research use only” vials and any use in people aren’t approved.
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and registries:
- Which version. PE-22-28, mini-spadin, spadin and the modified G/A versions are different peptides in the studies. The 23-hour figure belongs to the modified ones.
- Whose study. All four papers on PE-22-28 come from one research group, and the stroke paper’s authors disclose a patent application on propeptide pieces. Ask whether anyone else has repeated it.
- Mice aren’t people. Forced swim and similar tests screen for antidepressant-like activity in rodents. None has been run in a person.
- A claimed comparison. “Faster than antidepressants” needs a study that ran both; the PE-22-28 paper didn’t.
- The wrong parent. A page that calls it a piece of galanin, or tirzepatide, has the wrong peptide.
- Per-kilogram doses. The doses are for mice. A page quoting them as a human amount has no study behind it.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
What’s still unknown
- Whether it does anything for mood in a person.
- Whether anyone outside the originating lab gets the same results with PE-22-28 itself.
- Whether it reaches the brain by any route other than injection, and how long it lasts.
- Whether it is safe, given that the TREK-1 channel does different jobs in the brain and heart.
- Whether the stroke result holds up, given its two-way effect on the channel and the deaths at a higher early dose.
- Whether any blood test can measure PE-22-28 itself; the 2017 assay didn’t detect it.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention PE-22-28. We recheck every month. Last checked Nov 13, 2026.
We found no retracted, withdrawn or flagged studies that mention PE-22-28.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Heurteaux et al., 2006 | Nat Neurosci | No retraction or concern |
| Mazella et al., 2010 | PLoS Biol | No retraction or concern |
| Moha Ou Maati et al., 2012 | Neuropharmacology | No retraction or concern |
| Gil et al., 2012 | Am J Physiol Gastrointest Liver Physiol | No retraction or concern |
| Vallée et al., 2016 | Front Physiol | No retraction or concern |
| Hivelin et al., 2017 | Biochem Biophys Res Commun | No retraction or concern |
| Devader et al., 2017 | J Affect Disord | No retraction or concern |
| Hivelin et al., 2016 | J Diabetes Res | No retraction or concern |
| Djillani et al., 2017 | Front Pharmacol | No retraction or concern |
| Qi et al., 2018 | ACS Chem Neurosci | No retraction or concern |
| Roulot et al., 2018 | Neuropsychiatr Dis Treat | No retraction or concern |
| Djillani et al., 2019 | Pharmacol Ther | No retraction or concern |
| Mazella et al., 2018 | Front Pharmacol | No retraction or concern |
| Fang et al., 2019 | J Neuroinflammation | No retraction or concern |
| Pietri et al., 2019 | Neuropharmacology | No retraction or concern |
| Kamatham et al., 2019 | Pflugers Arch | No retraction or concern |
| Ma and Lewis, 2020 | Front Pharmacol | No retraction or concern |
| Busserolles et al., 2020 | Br J Pharmacol | No retraction or concern |
| García et al., 2021 | J Neurochem | No retraction or concern |
| Daziano et al., 2021 | Pharmacol Res | No retraction or concern |
| García et al., 2021 | Behav Brain Res | No retraction or concern |
| Chen et al., 2021 | Oxid Med Cell Longev | No retraction or concern |
| Zheng et al., 2022 | Mol Neurobiol | No retraction or concern |
| Kim et al., 2025 | Cell Death Dis | No retraction or concern |
| Mazella et al., 2025 | J Neurol Sci | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is PE-22-28?
A lab-made peptide of seven amino acids (Gly-Val-Ser-Trp-Gly-Leu-Arg), cut down from spadin, which is made from the sortilin protein. It is also called mini-spadin (Djillani et al., 2017; Mazella et al., 2018).
What is PE-22-28 used for?
It is sold for mood and brain-cell growth. The studies were in male mice and cells: forced-swim tests, new hippocampal cells, stroke and pancreatic cells. None was in a person (Djillani et al., 2017; Pietri et al., 2019).
Does PE-22-28 work?
Unknown in people. In male mice one lab found antidepressant-like results, and we found no study in a person and no repeat outside that lab (Djillani et al., 2017).
Is PE-22-28 safe?
Not shown. We found no safety study of it in any animal. Its parent spadin left several TREK-1-linked functions alone in one mouse screen, but other labs found it raised pain sensitivity in rats, and the stroke study of mini-spadin saw more deaths at a higher early dose (Moha Ou Maati et al., 2012; García et al., 2021; Pietri et al., 2019).
What are the side effects of PE-22-28?
Unknown. No study in people exists to report any. Side effects people report from online products come from users, not studies.
What is the PE-22-28 dosage?
We don’t give dosing advice. The amounts in the studies are per kilogram of a mouse, such as 3.0 to 4.0 micrograms for a single injection, and nobody has measured a dose in a person (Djillani et al., 2017).
Is PE-22-28 an antidepressant?
It acted like one in mouse tests, which is not the same as being one. It isn’t approved for depression, and no trial in people lists it (Djillani et al., 2017; ClinicalTrials.gov search).
Does PE-22-28 grow new brain cells?
In male mice, 4 days of treatment gave 1,736 new hippocampal cells against 899 on saline. Whether that happens in a person is unknown, and the paper didn’t compare it with an antidepressant (Djillani et al., 2017).
How long does PE-22-28 last?
In mice, two modified versions kept working for about 21 and 23 hours at higher doses on a behavior test, against about 6 hours for spadin. The figure for plain PE-22-28 isn’t given (Djillani et al., 2017).
Is PE-22-28 the same as spadin?
No. Spadin has 17 amino acids and PE-22-28 has 7. PE-22-28 blocked human TREK-1 in cells at about 0.1 to 0.12 nanomolar against 40 to 60 for spadin (Djillani et al., 2017).
Is PE-22-28 a piece of galanin?
No. The 2017 paper designed it from spadin’s breakdown products in blood, and galanin isn’t the source (Djillani et al., 2017).
Is PE-22-28 tirzepatide?
No. Tirzepatide is a much larger drug for GLP-1 and GIP receptors; see the tirzepatide page. PE-22-28 is seven amino acids that act on a potassium channel (PubChem).
Is there a PE-22-28 nasal spray?
Products are sold that way, but the mice in the studies were injected or given it by mouth. We found no study of a nasal route (Djillani et al., 2017).
Does PE-22-28 help with weight loss or blood sugar?
Not shown. Mini-spadin protected pancreas cells in dishes, and we found no animal or human study of PE-22-28 on weight or blood sugar (Daziano et al., 2021).
Is PE-22-28 FDA approved or legal?
It isn’t an approved drug, and the FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA). Our guide to what to look for covers the routes people use.
Sources
- Djillani A, et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017;8:643. PubMed 28955242
- Pietri M, et al. First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides. Neuropharmacology. 2019;158:107715. PubMed 31325429
- Daziano G, et al. Sortilin-derived peptides promote pancreatic beta-cell survival through CREB signaling pathway. Pharmacol Res. 2021;167:105539. PubMed 33737242
- Mazella J, et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol. 2010;8(4):e1000355. PubMed 20405001
- Moha Ou Maati H, et al. Spadin as a new antidepressant: absence of TREK-1-related side effects. Neuropharmacology. 2012;62(1):278-88. PubMed 21807005
- Heurteaux C, et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci. 2006;9(9):1134-41. PubMed 16906152
- Qi X, et al. Comparison of Therapeutic Effects of TREK1 Blockers and Fluoxetine on Chronic Unpredicted Mild Stress Sensitive Rats. ACS Chem Neurosci. 2018;9(11):2824-2831. PubMed 29952548
- Hivelin C, et al. Potentiation of Calcium Influx and Insulin Secretion in Pancreatic Beta Cell by the Specific TREK-1 Blocker Spadin. J Diabetes Res. 2016;2016:3142175. PubMed 28105440
- Djillani A, et al. Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin. Pharmacol Ther. 2019;194:185-198. PubMed 30291907
- Mazella J, et al. The Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1. Front Pharmacol. 2018;9:1541. PubMed 30670975
- Fang Y, et al. Deficiency of TREK-1 potassium channel exacerbates blood-brain barrier damage and neuroinflammation after intracerebral hemorrhage in mice. J Neuroinflammation. 2019;16(1):96. PubMed 31072336
- Zheng X, et al. The Two-Pore Domain Potassium Channel TREK-1 Promotes Blood-Brain Barrier Breakdown and Exacerbates Neuronal Death After Focal Cerebral Ischemia in Mice. Mol Neurobiol. 2022;59(4):2305-2327. PubMed 35067892
- Kamatham S, et al. TREK-1 protects the heart against ischemia-reperfusion-induced injury and from adverse remodeling after myocardial infarction. Pflugers Arch. 2019;471(10):1263-1272. PubMed 31511966
- Roulot M, et al. Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients. Neuropsychiatr Dis Treat. 2018;14:2307-2312. PubMed 30233189
- Mazella E, et al. Serum sortilin-derived propeptide concentrations as markers of depression in chronic stroke. J Neurol Sci. 2025;472:123459. PubMed 40107034
- Devader C, et al. Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients. J Affect Disord. 2017;208:443-447. PubMed 27838145
- García G, et al. PKC- and PKA-dependent phosphorylation modulates TREK-1 function in naïve and neuropathic rats. J Neurochem. 2021;157(6):2039-2054. PubMed 33006141
- García G, et al. TREK-1 potassium channels participate in acute and long-lasting nociceptive hypersensitivity induced by formalin in rats. Behav Brain Res. 2021;413:113446. PubMed 34224765
- Vallée N, et al. Fluoxetine Protection in Decompression Sickness in Mice is Enhanced by Blocking TREK-1 Potassium Channel with the "spadin" Antidepressant. Front Physiol. 2016;7:42. PubMed 26909044
- Busserolles J, et al. TREK1 channel activation as a new analgesic strategy devoid of opioid adverse effects. Br J Pharmacol. 2020;177(20):4782-4795. PubMed 32851651
- Chen T, et al. Controlled Decompression Attenuates Compressive Injury following Traumatic Brain Injury via TREK-1-Mediated Inhibition of Necroptosis and Neuroinflammation. Oxid Med Cell Longev. 2021;2021:4280951. PubMed 34790287
- Kim A, et al. Novel function of TREK-1 in regulating adipocyte differentiation and lipid accumulation. Cell Death Dis. 2025;16(1):164. PubMed 40057491
- Hivelin C, et al. Sortilin derived propeptide regulation during adipocyte differentiation and inflammation. Biochem Biophys Res Commun. 2017;482(1):87-92. PubMed 27816451
- Ma R, et al. Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels. Front Pharmacol. 2020;11:434. PubMed 32317978
- Gil V, et al. Relative contribution of SKCa and TREK1 channels in purinergic and nitrergic neuromuscular transmission in the rat colon. Am J Physiol Gastrointest Liver Physiol. 2012;303(3):G412-23. PubMed 22636169
- ClinicalTrials.gov. Search for spadin, mini-spadin and PE 22-28, November 13, 2026: no registered trial. Search
- U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for PE 22-28 and spadin, November 12, 2026: no match. openFDA
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
- World Anti-Doping Agency. 2026 Prohibited List, section S0. WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- National Library of Medicine. PubChem compound record: PE-22-28 (mini-spadin) (CID 165437303). PubChem
Last reviewed Nov 13, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.